Last reviewed · How we verify
The low-dose group of ZL-82 tablets
The low-dose group of ZL-82 tablets is a Small molecule drug developed by Chengdu Zenitar Biomedical Technology Co., Ltd. It is currently in Phase 2 development.
At a glance
| Generic name | The low-dose group of ZL-82 tablets |
|---|---|
| Sponsor | Chengdu Zenitar Biomedical Technology Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- The low-dose group of ZL-82 tablets CI brief — competitive landscape report
- The low-dose group of ZL-82 tablets updates RSS · CI watch RSS
- Chengdu Zenitar Biomedical Technology Co., Ltd portfolio CI
Frequently asked questions about The low-dose group of ZL-82 tablets
What is The low-dose group of ZL-82 tablets?
The low-dose group of ZL-82 tablets is a Small molecule drug developed by Chengdu Zenitar Biomedical Technology Co., Ltd.
Who makes The low-dose group of ZL-82 tablets?
The low-dose group of ZL-82 tablets is developed by Chengdu Zenitar Biomedical Technology Co., Ltd (see full Chengdu Zenitar Biomedical Technology Co., Ltd pipeline at /company/chengdu-zenitar-biomedical-technology-co-ltd).
What development phase is The low-dose group of ZL-82 tablets in?
The low-dose group of ZL-82 tablets is in Phase 2.